Triple Negative Breast Cancer

Clinical Trial Collaboration with Pfizer for TNBC Patients

Treatment of triple negative breast cancer (TNBC) is a significant medical need due to the aggressive nature of the disease and lack of treatment options. Recently, two PARP inhibitors, olaparib and talazoparib, have been approved for the treatment of local advanced HER2- breast cancers (including TNBC)  with germline BRCA mutations. However, only approximately 20% of the TNBC patients harbor a germline BRCA mutation and other TNBC patients are insensitive to PARP single agent inhibition. Recently, several prominent publications have shown that BET inhibitors can sensitize non-BRCA mutation patients to PARP inhibitors by modulating DNA repair genes. Zenith, in collaboration with Pfizer, is advancing ZEN-3694 + talazoparib (TALZENNA) into a combination Phase 1b/2 study in TNBC patients that do not have germline BRCA mutations